Dual targeting of CP-CML CD34+ cells with TKI and ALKs inhibitor affects cell proliferation and differentiation potential and reduces CD34+ cell numbers. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.